Posted by Michael Wonder on 25 Jan 2020
ICER posts draft scoping document for the assessment of treatments for haemophilia A
24 January 2020 - Document open to public comment until 13 February 2020.
The Institute for Clinical and Economic Review has posted a draft scoping document outlining a planned review of the comparative clinical effectiveness and value of valoctocogene roxaparvovec (BioMarin Pharmaceutical) and emicizumab (Hemlibra, Genentech) for the treatment of haemophilia A.
